DXC Technology Working With Ferrovial, Microsoft on AI Platform
By Chris Wack
DXC Technology said Friday that it will work with Ferrovial and Microsoft to jointly develop a generative artificial intelligence platform, called Quercus.
Quercus, which uses platform engineering principles as its foundations, would help organizations integrate secure, responsible AI technology throughout their business operations to automate processes for improved profitability and efficiency.
DXC said it will standardize Quercus and offer it as an AI platform for its global customers, tailoring the platform to meet individual customer needs. This will reduce the time required to create their own AI solutions.
DXC will be responsible for evolving, maintaining, and commercializing Quercus, which will run on Microsoft's Azure and OpenAI technology.
Ferrovial--the Spanish infrastructure company--has begun to implement an early version of the Quercus platform for its customers, creating an AI virtual assistant to support business activities including human resources, health and safety, tenders, and cybersecurity intelligent agents.
DXC said Quercus will be able to integrate with mission-critical business systems and coordinate with other generative AI models to increase potential performance impact for customers.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 17, 2024 08:04 ET (12:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks